PIPERINE IN THE PREVENTION OF THE DECREASED TAMOXIFEN SENSITIVITY IN MCF-7 BREAST CANCER CELL LINE | Zendy

Sandy Vitria Kurniawan | Zendy; Lies Sugiarti | Zendy; Septelia Inawati Wanandi | Zendy; Melva Louisa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PIPERINE IN THE PREVENTION OF THE DECREASED TAMOXIFEN SENSITIVITY IN MCF-7 BREAST CANCER CELL LINE

Author(s) -

Sandy Vitria Kurniawan,

Lies Sugiarti,

Septelia Inawati Wanandi,

Melva Louisa

Publication year - 2018

Publication title -

international journal of applied pharmaceutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.238

H-Index - 15

ISSN - 0975-7058

DOI - 10.22159/ijap.2018.v10s1.74

Subject(s) - piperine , tamoxifen , mcf 7 , breast cancer , p glycoprotein , viability assay , chemistry , pharmacology , medicine , cell , cancer research , cancer , biochemistry , multiple drug resistance , human breast , antibiotics

Objective: This study was designed to analyze the role of piperine in modulating P-glycoprotein mRNA expression when added in combination withtamoxifen to breast cancer cells in culture.Methods: MCF-7 breast cancer cells were treated with 1 μM tamoxifen with or without piperine (12.5, 25, or 50 μM) or verapamil 50 μM (P-glycoproteininhibitor positive control) for up to 12 days. We assessed the cell viability and isolated total RNA from them. We quantified P-glycoprotein expressionsusing quantitative reverse transcription polymerase chain reaction.Results: Administration of various doses of piperine decreased MCF-7 breast cancer cell viability. Piperine, when given in combination with tamoxifen,decreased the expression of P-glycoprotein mRNA in cells compared with the expression in cells treated with tamoxifen only. The effects were shownto be dose dependent.Conclusion: Piperine prevents the development of breast cancer cell tamoxifen resistance, probably through its inhibition of P-glycoprotein expression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research